Paul J. Newey

Paul J. Newey

Auto-generated profile, based on publicly available information

Paul J. Newey

Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
PNPaul J Newey
Paul J Newey
JNJohn Newell-Price
John Newell-Price
Clinical practice guidelines for patients with multiple endocrine neoplasia type 1 (MEN1) recommend a variety of surveillance options. Given progress over the past decade in this area, it is timely to evaluate their ongoing utility. MEN1 is characterized by the development of synchronous or asynchronous tumors affecting a multitude of endocrine and nonendocrine tissues, resulting in premature morbidity and mortality, such that the rationale for undertaking surveillance screening in at-risk individuals appears robust. Current guidelines recommend an intensive regimen of clinical, biochemical, and radiological surveillance commencing in early childhood for those with a clinical or genetic diagnosis of MEN1, with the aim of early tumor detection and treatment. Although it is tempting to assume that such screening results in patient benefits and improved outcomes, the lack of a strong evidence base for several aspects of MEN1 care, and the potential for iatrogenic harms related to screening tests or interventions of unproven benefit, make such assumptions potentially unsound. Furthermore, the psychological as well as economic burdens of intensive screening remain largely unstudied. Although screening undoubtedly constitutes an important component of MEN1 patient care, this perspective aims to highlight some of the current uncertainties and challenges related to existing MEN1 guidelines with a particular focus on the role of screening for presymptomatic tumors. Looking forward, a screening approach that acknowledges these limitations and uncertainties and places the patient at the heart of the decision-making process is advocated.

18 June 2018 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
PMPavithran Maniam
Pavithran Maniam
KZKaixin Zhou
Kaixin Zhou
MLMike Lonergan
Mike Lonergan
JBJonathan N Berg
Jonathan N Berg
DGDavid R Goudie
David R Goudie
PNPaul J Newey
Paul J Newey
Germline SDHA mutations are reported in a minority of pheochromocytoma/paraganglioma (PPGL) cases, but are associated with an increased risk of malignancy, leading some to advocate cascade genetic testing and surveillance screening of ‘at-risk’ first-degree relatives. However, such approaches rely on accurate estimates of variant pathogenicity and disease penetrance, which may have been subject to ascertainment and reporting biases, although the recent provision of large population-based DNA sequence datasets may provide a potentially unbiased resource to aid variant interpretation. Thus, the aim of the current study was to evaluate the pathogenicity and penetrance of SDHA variants reported in literature-based PPGL cases, by comparing their frequency to those occurring in the GnomAD dataset, which provides high-quality DNA sequence data on 138,632 individuals. In total, 39 different missense or loss-of-function (LOF) SDHA variants were identified in 95 PPGL index cases. Notably, many of the PPGL-associated SDHA alleles were observed at unexpectedly high frequency in the GnomAD cohort, with ∼1% and ∼0.1% of the background population harboring a rare missense or LOF variant, respectively. Although the pathogenicity of several SDHA alleles was supported by significant enrichment in PPGL cases relative to GnomAD controls, calculations of disease penetrance based on allele frequencies in the respective cohorts, resulted in much lower estimates than previously reported, ranging from 0.1-4.9%. Thus, whilst this study provides support for the etiological role of SDHA in PPGL formation, it suggests that the majority of variant carriers will not manifest PPGL and are unlikely to benefit from periodic surveillance screening.

15 November 2018 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CGCaroline M Gorvin
Caroline M Gorvin
PNPaul J Newey
Paul J Newey
ARAngela Rogers
Angela Rogers
VSVictoria Stokes
Victoria Stokes
MNMatt J Neville
Matt J Neville
RTRajesh V Thakker
Rajesh V Thakker
Prolactinomas are the most frequent type of pituitary tumors, which represent 10–20% of all intracranial neoplasms in humans. Prolactinomas develop in mice lacking the prolactin receptor (PRLR), which is a member of the cytokine receptor superfamily that signals via Janus kinase-2-signal transducer and activator of transcription-5 (JAK2-STAT5) or phosphoinositide 3-kinase-Akt (PI3K-Akt) pathways to mediate changes in transcription, differentiation and proliferation. To elucidate the role of the PRLR gene in human prolactinomas, we determined the PRLR sequence in 50 DNA samples (35 leucocytes, 15 tumors) from 46 prolactinoma patients (59% males, 41% females). This identified six germline PRLR variants, which comprised four rare variants (Gly57Ser, Glu376Gln, Arg453Trp and Asn492Ile) and two low-frequency variants (Ile76Val, Ile146Leu), but no somatic variants. The rare variants, Glu376Gln and Asn492Ile, which were in complete linkage disequilibrium, and are located in the PRLR intracellular domain, occurred with significantly higher frequencies (P < 0.0001) in prolactinoma patients than in 60 706 individuals of the Exome Aggregation Consortium cohort and 7045 individuals of the Oxford Biobank. In vitro analysis of the PRLR variants demonstrated that the Asn492Ile variant, but not Glu376Gln, when compared to wild-type (WT) PRLR, increased prolactin-induced pAkt signaling (>1.3-fold, P < 0.02) and proliferation (1.4-fold, P < 0.02), but did not affect pSTAT5 signaling. Treatment of cells with an Akt1/2 inhibitor or everolimus, which acts on the Akt pathway, reduced Asn492Ile signaling and proliferation to WT levels. Thus, our results identify an association between a gain-of-function PRLR variant and prolactinomas and reveal a new etiology and potential therapeutic approach for these neoplasms.

21 December 2021 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
PNPaul J. Newey
Paul J. Newey
FHFadil Hannan
Fadil Hannan
AWAbbie Wilson
Abbie Wilson
RTRajesh V. Thakker
Rajesh V. Thakker
Disorders of calcium homeostasis are the most frequent metabolic bone and mineral disease encountered by endocrinologists. These disorders usually manifest as primary hyperparathyroidism (PHPT) or hypoparathyroidism (HP), which have a monogenic aetiology in 5%–10% of cases, and may occur as an isolated endocrinopathy, or as part of a complex syndrome. The recognition and diagnosis of these disorders is important to facilitate the most appropriate management of the patient, with regard to both the calcium‐related phenotype and any associated clinical features, and also to allow the identification of other family members who may be at risk of disease. Genetic testing forms an important tool in the investigation of PHPT and HP patients and is usually reserved for those deemed to be an increased risk of a monogenic disorder. However, identifying those suitable for testing requires a thorough clinical evaluation of the patient, as well as an understanding of the diversity of relevant phenotypes and their genetic basis. This review aims to provide an overview of the genetic basis of monogenic metabolic bone and mineral disorders, primarily focusing on those associated with abnormal calcium homeostasis, and aims to provide a practical guide to the implementation of genetic testing in the clinic.

29 June 2019 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
PNPaul J. Newey
Paul J. Newey

1 December 2021 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
PNPaul J. Newey
Paul J. Newey